(E)-3-(2,5-dimethoxyphenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-3-(2,5-dimethoxyphenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
• 英文别名: 2'-Hydroxy-2,4',5-trimethoxychalcone
• 化学式: C₁₈H₁₈O₅
• 分子量: 314.338
• InChiKey: KLEXWSHSPRMPQS-XBXARRHUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (E)-3-(2,5-dimethoxyphenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙酸乙酯 为溶剂， 以81%的产率得到3-(2,5-dimethoxyphenyl)-1-(2-hydroxy-4-methoxyphenyl)propan-1-one
  参考文献：
  名称：

  查尔酮，二氢查耳酮和1,3-二芳基丙烷类似物作为抗炎剂的合成和生物学评估。

  摘要：

  通过醛醇缩合制备二十一个查耳酮，随后将这些化合物还原，得到相应的二氢查耳酮和1，3-二苯基丙烷衍生物。检查了合成产物对LPS活化的小鼠腹膜巨噬细胞中NO抑制的影响。在测试的化合物中，1,3-二芳基丙烷类似物2-（3-（3,4-二甲氧基苯基）丙基）-5-甲氧基苯酚（3p）对NO的产生表现出最显着的抑制作用。为了研究作用机理，通过免疫印迹研究了3p对iNOS和COX-2蛋白表达的影响。结果得出结论，3p能够通过ERK，p38和JNK减弱NF-κB信号传导而抑制LPS诱导的RAW264.7细胞中的iNOS表达。

  DOI：

  10.1016/j.bmcl.2017.02.038
• 作为产物：
  描述：

  丹皮酚 、 2,5-二甲氧基苯甲醛 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 生成 (E)-3-(2,5-dimethoxyphenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
  参考文献：
  名称：

  四种含有甲氧基取代基的 (E)-1-(2-羟基苯基)-3-phenylprop-2-en-1-one 衍生物的晶体结构、Hirshfeld 表面分析和 PIXEL 计算。π 相互作用的重要性

  摘要：

  摘要 对四种具有不同数量甲氧基取代基的查耳酮 (E)-1-(2-羟基苯基)-3-苯基丙-2-en-1-one 衍生物进行了详细的结构分析，即 (E)- 3-(3,4-二甲氧基苯基)-1-(2-羟基苯基)prop-2-en-1-one, (1), (E)-3-(4-甲氧基苯基)-1-(2-羟基- 4-甲氧基苯基)prop-2-en-1-one, 2, (E)-3-(2,5-二甲氧基苯基)-1-(2-羟基-4-甲氧基苯基)prop-2-en-1-one 、3 和 (E)-3-(2,5-二甲氧基苯基)-1-(2-羟基-3,4-二甲氧基苯基)prop-2-en-1-one, 4. 晶体结构在 100 K 下测定通过单晶 X 射线衍射。由于二聚亚结构的形成需要显着的苯基旋转以最小化空间位阻，因此化合物 2 在两个独立分子中的苯基之间显示出出乎意料的大 25 和 28,o 面间角。在 1、3 和 4

  DOI：

  10.1016/j.molstruc.2020.128652

文献信息

• Differential effects of synthesized 2′-oxygenated chalcone derivatives: modulation of human cell cycle phase distribution
  作者：Yerra Koteswara Rao、Shih-Hua Fang、Yew-Min Tzeng

  DOI：10.1016/j.bmc.2004.03.014

  日期：2004.5

  Ten structurally related T-oxygenated chalcone derivatives, bearing either hydroxy and/or methoxy substituents oil the A and B rings, were synthesized through Claisen-Schmidt condensation. The synthesis procedure was relatively easy and had an acceptable yield. The in vitro cytotoxicities of these compounds against the human tumor cells such as Jurkat, U937 cells, and normal cells PHA stimulated PBMCs were investigated. Among those, compounds 1 (IC50 = 2.5 muM), 2 (1.7 muM), and 8 (3.2 muM) showed potent inhibitory activity toward Jurkat cell line. In parallel, compounds 1 (6.7 muM), 2 (1.5 muM), and 10 (5.3 muM) showed the highest activity against U937 cell line. However, the chalcones also inhibit the PHA stimulated PBMCs cells, but the IC50 values were relatively high when compared to the tumor cell line values. Studies were also on the effect of synthesized chalcones on the cell cycle phase distribution. In Jurkat cell line, compounds 7 and 9 showed the highest activity and the most striking effect in reduction of the percentage of cells in the S phase, which was associated with an increase of cells in G2/M phase. In U937 cell line, compound 3 increased the proportion of cells in the G0/G1 phase and reduced the proportion in S phase. In contrast, compounds 1, 9, and 10 showed a decrease effect on the percentage of cells in S phase and an increase effect on the percentage of cells in the G2/M phase of the cell cycle. Whereas in the case of PHA stimulated PBMCs, compounds 1, 4, 8, and 10 increased the percentage of cells in G2/M phase, which was associated with a decrease effect in the :S phase of the cell cycle. (C) 2004 Elsevier Ltd. All rights reserved.
• ——
  作者：Christelle Pouget、Catherine Fagnere、Jean‐Philippe Basly、Anne‐Elise Besson、Yves Champavier、Gerard Habrioux、Albert‐Jose Chulia

  DOI：10.1023/a:1014490817731

  日期：——

  Purpose. Aromatase inhibitors are known to prevent the conversion of androgens to estrogens and play a significant role in the treatment of estrogen dependent diseases such as breast cancer. Some flavonoids have been reported as potent aromatase inhibitors: therefore. in an effort to develop novel anti breast cancer agents. B ring substituted flavanones with a 7-methoxy group on A ring were synthesized and tested to assess their ability to inhibit aromatase activity and to determine the optimal B ring substitution pattern.Methods. A series of flavanones was prepared by cyclisation of 2'-hydroxychalcones previously obtained by Claisen-Schmidt condensation and the aromatase inhibitory activity or these compounds was investigated using human placental microsomes and radiolabeled [1.2,6,7-H-3]-androstenedione as substrate.Results. Almost all flavanones exhibited inhibitory effect on the aromatase activity but their potency was dependent on their B ring subtitution pattern. Hydroxylation at position 3' and/or 4' enhanced the anti-aromatase activity thus, 3'.4'-dihydroxy-7-methoxyflavanone was found to he twice more potent than aminoglutethimide. the first aromatase inhibitor clinically used.Conclusions. These results indicated that these flavanones could be considered as potential anti breast cancer agents through the inhibition of aromatase activity and allowed us to select some of these Compounds as skeleton for the development of flavonoid structurally-related aromatase inhibitors.
• Antimitotic and Antiproliferative Activities of Chalcones: Forward Structure–Activity Relationship
  作者：Ahcène Boumendjel、Julien Boccard、Pierre-Alain Carrupt、Edwige Nicolle、Madeleine Blanc、Annabelle Geze、Luc Choisnard、Denis Wouessidjewe、Eva-Laure Matera、Charles Dumontet

  DOI：10.1021/jm0708331

  日期：2008.4.1

  A series of 59 chalcones was prepared and evaluated for the antimitotic effect against K562 leukemia cells. The most active chalcones were evaluated for their antiproliferative activity against a panel of I I human and murine cell cancer lines. We found that three chalcones were of great interest as potential antimitotic drugs. In vivo safety studies conducted on one of the most active chalcones revealed that the compound was safe, allowing further in vivo antitumor evaluation.
• Compounds exhibiting efflux inhibitor activity and composition and uses thereof
  申请人：Wempe Fitzpatrick Michael

  公开号：US20070254859A1

  公开（公告）日：2007-11-01

  At least one compound chosen from compounds of Formula I: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a prodrug thereof, and mixtures of any of the foregoing, wherein: n is a number from 1 to 900, wherein the individual units may be the same or different; W is chosen from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; each of R 2 , R 3 , R 4 and R 5 is independently chosen from —H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; Z′ is chosen from —O—, —N—, —NO—, —NR 4 —, —S—, —SO— and —SO 2 —, wherein R 4 is defined as above; each of X, X′, Y and Z is independently chosen from —CR 4 R 5 —, —NH—, —NR 4 —, —NO—, —O—, —NOR 4 —, —S—, —SO—, —SO 2 —, wherein R 4 and R 5 are defined as above; R 1 is chosen from a tocopherol, a steroid and a flavonoid; and R 6 is chosen from any R 1 , alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl.
• [EN] COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSES PRESENTANT UNE ACTIVITE INHIBITRICE DE L'ECOULEMENT, COMPOSITIONS ET UTILISATIONS DE CEUX-CI
  申请人：EASTMAN CHEM CO

  公开号：WO2007115181A9

  公开（公告）日：2008-04-03

  [EN] At least one compound chosen from compounds of Formula 1: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a prodrug thereof, and mixtures of any of the foregoing, wherein: n is a number from 1 to 900, wherein the individual units may be the same or different; W is chosen from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; each Of R₂, R₃, R₄ and R₅ is independently chosen from -H, alkyl, substituted aikyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; Z' is chosen from -O-, -N-, -NO-, - NR₄-, -S-, -SO- and -SO₂-, wherein R₄ is defined as above; each of X, X', Y and Z is independently chosen from -CR₄R₅-, -NH-, -NR₄-, -NO-. -O-, -NOR₄-, -S-, -SO-, -SO₂-, wherein R₄ and R₅ are defined as above; R₁ is chosen from a tocopherol, a steroid and a flavonoid; and R₆, is chosen from any R₁, alkyl. substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl.
  [FR] La présente invention concerne au moins un composé choisi parmi les composés de formule 1 : un sel ou un ester pharmaceutiquement acceptable de celui-ci, un solvate de celui-ci, un chélate de celui-ci, un complexe non covalent de celui-ci, un promédicament de celui-ci et des mélanges de ces derniers, n étant un nombre de 1 à 900, les unités individuelles pouvant être identiques ou différentes, W étant choisi parmi l'alkyle, l'alkyle substitué, le cycloalkyle, le cycloalkyle substitué, l'aryle, l'aryle substitué, l'aralkyle et l'aralkyle substitué, R₂, R₃, R₄ et R₅ étant chacun indépendamment choisi parmi -H, alkyle, alkyle substitué, cycloalkyle, cycloalkyle substitué, aryle, aryle substitué, aralkyle et aralkyle substitué, Z' étant choisi parmi -O-, -N-, -NO-, - NR₄-, -S-, -SO- et -SO₂-, R₄ étant tel que défini ci-dessus, X, X', Y et Z étant chacun indépendamment choisi parmi -CR₄R₅-, -NH-, -NR₄-, -NO-, -O-, -NOR₄-, -S-, -SO-, -SO₂-, R₄ et R₅ étant tels que définis ci-dessus, R₁ étant choisi parmi un tocophérol, un stéroïde et un anthoxanthine, et R₆ étant choisi parmi R₁, alkyle, alkyle substitué, cycloalkyle, cycloalkyle substitué, aryle, aryle substitué, aralkyle et aralkyle substitué.